304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2021-03-28

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint
2021-03-19

Henlius Bevacizumab Has Received IND Approval from US FDA for the Treatment of wAMD
2021-03-11

First Patient Dosed in Phase II/III Clinical Trial of Henlius Anti-PD-1 mAb HLX10 Combined with Bevacizumab for the First-line Treatment of mCRC
2021-01-29

Henlius Bevacizumab Has Received Clinical Trial Approval in Australia
2021-01-14

Henlius Has Reached an Exclusive License Agreement with Chiome for Antibodies Targeting Human TROP2
2021-01-13

Henlius Daratumumab Biosimilar Received IND Approval from NMPA
2020-12-17

NMPA Has Accepted The NDA of HLX01(Rituximab Injection) for the Treatment of Rheumatoid Arthritis
2020-12-07

Henlius Adalimumab Biosimilar 汉达远® Approved by NMPA
2020-11-20

Henlius Released Phase 3 Study Data of its Bevacizumab Biosimilar HLX04 at ESMO Asia 2020